A Decision Analysis of Alternative Treatment Strategies for Clinically Localized Prostate Cancer

JAMA: The Journal of the American Medical Association

Volumn 269, Issue 20, 1993, Pages 2650-2658

  Fleming, Craig ^a   Wasson, John H ^b   Albertsen, Peter C ^c   Barry, Michael J ^d,e   Wennberg, John E ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e HENRY J KAISER FAMILY FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CONSERVATIVE TREATMENT; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; STATISTICAL ANALYSIS; TUMOR DIFFERENTIATION;

AGED; DECISION SUPPORT TECHNIQUES; HORMONES; HUMAN; MALE; MIDDLE AGE; NEOPLASM METASTASIS; PROBABILITY; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIOTHERAPY; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0027322922     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1993.03500200064035     Document Type: Article

References (42)

1. Wasson JH, Cushman CC, Bruskewitz RC, et al. A structured literature review of treatment for localized prostate cancer. Arch Fam Med. 1993;2: 487-493.
2. Gallee MPW, ten Kate FJW, Mulder DG, Blom JHM, Van der Heul RO. Histological grading of prostatic carcinoma in prostatectomy specimens: comparison of prognostic accuracy of five grading systems. Br J Urol. 1990;65:368-375.
3. Donohue RE, Miller GJ. Adenocarcinoma of the prostate: biopsy to whole mount: Denver VA experience. Urol Clin North Am. 1991;18:449-452.
4. Lange HP, Narayan P. Understaging and undergrading of prostate cancer: argument for postoperative radiation as adjuvant therapy. Urology. 1983;21:113-118.
5. Christensen WN, Partin AW, Walsh PC, Epstein JI. Pathologic findings in clinical stage A2 prostate cancer: relation of tumor volume, grade, and location to pathologic stage. Cancer. 1990;65: 1021-1027.
6. Larsen MP, Carter HB, Epstein JI. Can stage Al tumor extent be predicted by transurethral resection tumor volume, percent or grade? a study of 64 stage Al radical prostatectomies with comparison to prostates removed for stages A2 and B disease. J Urol. 1991;146:1059-1063.
7. Villers AA, McNeal JE, Freiha FS, Stamey TA. Development of prostatic carcinoma: morphometric and pathologic features of early stages. Acta Oncol. 1991;30:145-151.
8. Catalona WJ, Stein AJ. Staging errors in clinically localized prostatic cancer. J Urol. 1982;127: 452-456.
9. Ebert T, Schmitz-Dräger BJ, Bürrig KF, et al. Accuracy of imaging modalities in staging the local extent of prostate cancer. Urol Clin North Am. 1991;18:453-457.
10. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making. 1983;3:419-458.
11. Roach PJ, Fleming C, Hagen MD, Pauker SG. Prostatic cancer in a patient with asymptomatic HIV infection: are some lives more equal than others? Med Decis Making. 1988;8:132-144.
12. Sonnenberg FA, Pauker SG, Kassirer JP. Decision Maker 7.0. Boston, Mass: Pratt Medical Group; 1991.
13. Haapiainen R, Rannikko S, Mäkinen J, Alfthan O. T0 carcinoma of the prostate: influence of tumor extent and histologic grade on prognosis of untreated patients. Eur Urol. 1986;12:16-20.
14. Johansson J-E, Adami H-O, Andersson S-O, Bergström R, Krusemo UB, Kraaz W. Natural history of localised prostatic cancer: a population-based study in 223 untreated patients. Lancet. 1989;1: 799-803.
15. Zhang G, Wasserman NF, Sidi AM, et al. Long-term follow-up results after expectant management of stage A1 prostatic cancer. J Urol. 1991;146:99-103.
16. Blackard CE, Mellinger GT, Gleason DF. Treatment of stage 1 carcinoma of the prostate: a preliminary report. J Urol. 1971;106:729-733.
17. Byar DP, VACUR Group. Survival of patients with incidentally found microscopic cancer of the prostate: results of a clinical trial of conservative treatment. J Urol. 1972;108:908-912.
18. Zincke H, Blute M, Fallen M, Farrow G. Radical prostatectomy for stage A adenocarcinoma of the prostate: staging errors and their implications for treatment recommendations and disease outcome. J Urol. 1991;146:1053-1058.
19. Fowler JE, Mills SE. Operable prostatic carcinoma: correlations among clinical stage, pathological stage, Gleason histologic score and early disease-free survival. J Urol. 1985;133:49-52.
20. Paulson DF, Robertson J, Daubert L, Walther P. Radical prostatectomy in stage A prostatic adenocarcinoma. J Urol. 1988;140:535-538.
21. Scardino PT, Wheeler TM. Prostatic biopsy after irradiation therapy for prostatic cancer. Urol. 1985;25:39-48.
22. Paulson DF, Lin GH, Hinshaw W, et al. Radical surgery versus radiotherapy for adenocarcinoma of the prostate. J Urol. 1982;128:502-504.
23. Hanks GE. Radiotherapy or surgery for prostate cancer: ten and fifteen year results of external beam therapy. Acta Oncol. 1991;30:231-237.
24. Lu-Yao GL, McLerran D, Wasson J, Wennberg JE, for the Prostate Patient Outcomes Research Team. An assessment of radical prostatectomy: time trends, geographic variation, and outcomes. JAMA. 1993;269:2633-2636.
25. National Center for Health Statistics. Vital Statistics of the United States, 1986, Vol II: Mortality Part A. Washington, DC: US Dept of Health and Human Services; 1986. Publication PHS 86-1101.
26. Drago JR, Badalament RA, Nesbitt JA. Radical prostatectomy 1972-1987: single institution experience: comparison of standard radical prostatectomy and nerve-sparing technique. Urology. 1990; 35:377-380.
27. Catalona WJ, Bigg SW. Nerve-sparing radical prostatectomy: evaluation of results after 250 patients. J Urol. 1990;143:538-543.
28. Quinlan DM, Epstein JI, Carter BS, Walsh PC. Sexual function following radical prostatectomy: influence of preservation of neurovascular bundles. J Urol. 1991;145:998-1002.
29. Walsh PC, Epstein JI, Lowe FC. Potency following radical prostatectomy with wide unilateral excision of the neurovascular bundle. J Urol. 1987; 138:823-827.
30. Barry MJ, Mulley Jr AG, Fowler FJ, Wennberg JW. Watchful waiting vs immediate transurethral resection for symptomatic prostatism: the importance of patients’ preferences. JAMA. 1988;259: 3010-3017.
31. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989;321:419-424.
32. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med. 1977;296:716-721.
33. Idler E, Kasl S. Health perceptions and survival: do global evaluations of health status really predict mortality? J Gerontol. 1991;46:555-565.
34. McNeil BJ, Pauker SG, Sox HC, Tversky A. On the elicitation of preferences for alternative therapies. N Engl J Med. 1982;306:1259-1262.
35. Mulley AG. Assessing patients’ utilities: can the ends justify the means? Med Care. 1989;27: 5269-5281.
36. Oesterling JE, Brendler CB, Epstein JI, Kimball AW Jr, Walsh PC. Correlation of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade with final pathological stage in 257 patients with clinically localized adenocarcinoma of the prostate. J Urol. 1987;138:92-98.
37. McNeal JE, Villers AA, Redwine EA, Freiha FS, Stamey TA. Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer. 1990;66:1225-1233.
38. Eckman MH, McNutt RA, Parkinson DR, Pauker SG. The timing of radical cystectomy after recent myocardial infarction: waiting for Godot. Med Decis Making. 1987;7:52-66.
39. Epstein JI, Steinberg GD. The significance of low-grade prostate cancer on needle biopsy: a radical prostatectomy study of tumor grade, volume, and stage of the biopsied and multifocal tumor. Cancer. 1990;66:1927-1932.
40. Johansson J-E, Adami HO, Andersson S-O, Bergström R, Holmberg L, Krusemo UB. High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA. 1992;267:2191-2196.
41. Dole R. 34 000 men a year. Washington Post. January 5, 1993:A15.
42. Byar DP, Corle DK. The Veterans Administration Cooperative Urological Research Group. Urology. 1981;17(suppl):7-11.